Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

• Published in: Clinical cancer research 2023-02, Vol.29 (3), p.532-540
• Main Authors: Matikas, Alexios, Johansson, Hemming, Grybäck, Per, Bjöhle, Judith, Acs, Balazs, Boyaci, Ceren, Lekberg, Tobias, Fredholm, Hanna, Elinder, Ellinor, Margolin, Sara, Isaksson-Friman, Erika, Bosch, Ana, Lindman, Henrik, Adra, Jamila, Andersson, Anne, Agartz, Susanne, Hellström, Mats, Zerdes, Ioannis, Hartman, Johan, Bergh, Jonas, Hatschek, Thomas, Foukakis, Theodoros
• Format: Article
• Language: English
• Subjects: Ado-Trastuzumab Emtansine - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Female; Humans; Lymphocytes, Tumor-Infiltrating; Medicin och hälsovetenskap; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Receptor, ErbB-2 - metabolism; Trastuzumab
• ISSN: 1078-0432; 1557-3265; 1557-3265
• DOI: 10.1158/1078-0432.CCR-22-2829

PREDIX HER2 is a randomized Phase II trial that compared neoadjuvant docetaxel, trastuzumab, and pertuzumab (THP) with trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Rates of pathologic complete response (pCR) did not differ between the two groups. Here, we present the survival outcomes from PREDIX HER2 and investigate metabolic response and tumor-infiltrating lymphocytes (TIL) as prognostic factors. In total, 202 patients with HER2-positive breast cancer were enrolled and 197 patients received six cycles of either THP or T-DM1. Secondary endpoints included event-free survival (EFS), recurrence-free survival (RFS), and overall survival (OS). Assessment with PET/CT was performed at baseline, after two and six treatment cycles. TILs were assessed manually at baseline biopsies, while image-based evaluation of TILs [digital TILs (DTIL)] was performed in digitized full-face sections. After a median follow-up of 5.21 years, there was no difference between the two treatment groups in terms of EFS [HR = 1.26; 95% confidence interval (CI), 0.54-2.91], RFS (HR = 0.69; 95% CI, 0.24-1.93), or OS (HR = 0.52; 95% CI, 0.09-2.82). Higher SUVmax at cycle 2 (C2) predicted lower pCR (ORadj = 0.65; 95% CI, 0.48-0.87; P = 0.005) and worse EFS (HRadj = 1.27; 95% CI, 1.12-1.41; P < 0.001). Baseline TILs and DTILs provided additional prognostic information to clinical parameters and C2 SUVmax. Long-term outcomes following neoadjuvant T-DM1 were similar to neoadjuvant THP. SUVmax after two cycles of neoadjuvant therapy for HER2-positive breast cancer may be an independent predictor of both short- and long-term outcomes. Combined assessment with TILs may facilitate early selection of poor responders for alternative treatment strategies.